China

Braveheart Bio will make an initial payment of US$65 million to Hengrui Pharma, with half of the amount paid in cash and the other half in Braveheart Bio’s equity

SNUG01 is a pioneering gene therapy that uses a recombinant adeno-associated virus serotype 9 (rAAV9) to deliver the human TRIM72 protein to the central nervous system, particularly targeting motor neurons.

The drug has already gained approvals in Singapore, Hong Kong SAR, and Macao SAR, and its NDA has been accepted in South Korea.

XH-S004 is an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor designed to treat inflammatory respiratory diseases.

NEFECON® is the first and only treatment that targets the cause of IgA nephropathy (IgAN) to receive full approval in China, the United States, and Europe.

The NMPA of China has approved LENVIMA with pembrolizumab and TACE for treating unresectable, non-metastatic hepatocellular carcinoma (HCC).

The net payment for the acquisition will be approximately US$501 million, as this figure excludes LaNova’s estimated cash and bank deposits of around US$450 million.

This state-of-the-art facility focuses on the research, development, and manufacturing of semi-finished components used in bioresorbable medical devices.

Under the terms of the agreement, Otsuka will obtain exclusive global rights to develop, manufacture, and commercialize HBM7020 outside of Greater China.